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Leprosy is a chronic infectious disease caused by My-
cobacterium leprae. This disease predominantly affects 
the skin and peripheral nerves and can cause significant 
nerve destruction, leading to handicaps and/or deformi-
ties (Scollard 2008). Leprosy is a spectral disease: the 
clinical manifestations are dependent on the host im-
mune response (Ridley & Jopling 1966). At one end of 
the spectrum, lepromatous leprosy (LL) patients exhibit 
a higher bacterial index (BI), high titres of M. leprae-spe-
cific antibodies and limited or no specific cell-mediated 
immunity. By contrast, tuberculoid leprosy (TT) patients 
demonstrate no detectable BI, low or absent titres of M. 
leprae-specific antibodies and significant specific cell-
mediated immunity (CMI) (Chanteau et al. 1989, Cho et 
al. 1991, Sampaio et al. 2011). Other borderline forms oc-
cupy the spectrum between the humoral-dominated LL 
form and the CMI-dominated TT form: borderline lep-
romatous (BL), borderline-borderline (BB) and border-
line tuberculoid (BT) (Ridley & Jopling 1966). Accord-
ing to the BI of the patients, TT/BT forms are regarded as 
paucibacillary (PB) and BB/BL/ LL forms are considered 
multibacillary (MB) disease.
Despite the success of multidrug therapy (MDT) in 
reducing the number of registered leprosy cases world-
wide, approximately 210,000 newly diagnosed patients 
are still registered every year (WHO 2010). The MDT 
drug regimen and its duration vary for PB and MB lep-
rosy. In 1998, the World Health Organization recom-
mended a simplified operational leprosy classification 
system for PB and MB leprosy based on the number of 
skin lesions: patients with up to five lesions were desig-
nated as PB and patients with six or more lesions were 
designated as MB. Currently, leprosy diagnosis is still 
based on clinical symptoms and early diagnosis and 
treatment are crucial to prevent disability and further 
transmission (Dockrell et al. 2011). Sensitive and spe-
cific laboratory tests are not available for the diagnosis 
of leprosy. The presence of antibodies against phenolic 
glycolipid-I (PGL-I), an immunodominant M. leprae-
specific antigen, correlates with a higher BI in leprosy 
patients (LPs) (Douglas & Worth 1984, Chujor et al. 1991, 
Bührer-Sékula et al. 2003). ELISA, particle agglutina-
tion, dipstick tests and rapid lateral-flow tests have been 
developed to detect anti-PGL-I IgM antibodies (Brett et 
al. 1986, Petchclai et al. 1988, Bührer-Sékula et al. 2003). 
The anti-PGL-I serology reflects the leprosy spectrum 
and BI positivity: high positive rates are found among 
MB patients and low positive rates are found among PB 
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The diagnosis of leprosy continues to be based on clinical symptoms and early diagnosis and treatment are criti-
cal to preventing disability and transmission. Sensitive and specific laboratory tests are not available for diagnosing 
leprosy. Despite the limited applicability of anti-phenolic glycolipid-I (PGL-I) serology for diagnosis, it has been 
suggested as an additional tool to classify leprosy patients (LPs) for treatment purposes. Two formats of rapid tests 
to detect anti-PGL-I antibodies [ML immunochromatography assay (ICA) and ML Flow] were compared in differ-
ent groups, multibacillary patients, paucibacillary patients, household contacts and healthy controls in Brazil and 
Nepal. High ML Flow intra-test concordance was observed and low to moderate agreement between the results of 
ML ICA and ML Flow tests on the serum of LPs was observed. LPs were “seroclassified” according to the results 
of these tests and the seroclassification was compared to other currently used classification systems: the World 
Health Organization operational classification, the bacilloscopic index and the Ridley-Jopling classification. When 
analysing the usefulness of these tests in the operational classification of PB and MB leprosy for treatment and 
follow-up purposes, the ML Flow test was the best point-of-care test for subjects in Nepal and despite the need for 
sample dilution, the ML ICA test yielded better performance among Brazilian subjects. Our results identified pos-
sible ways to improve the performance of both tests. 
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patients (Moura et al. 2008). Therefore, despite its lim-
ited application for the general diagnosis of leprosy, anti-
PGL-I serology has been suggested as an auxiliary tool 
to differentiate between PB and MB LPs to prescribe the 
corresponding MDT regimen. As a point-of-care (POC) 
test, the anti-PGL-I rapid lateral flow test is easy to per-
form, does not require refrigeration or other devices and 
can be implemented in the outpatient routine to aid the 
classification of patients as PB or MB for treatment pur-
poses. The combination of clinical examination and anti-
PGL-I testing can lead to a significant reduction in the 
misclassification of LPs, compared with lesion counting 
alone (Bührer-Sékula et al. 2003, 2009). The use of a 
rapid anti-PGL-I test to correctly classify patients can 
facilitate the prescription of the appropriate MDT regi-
men and the prevention of transmission. 
In 2004, an international research consortium, Ini-
tiative for Diagnostic and Epidemiological Assays for 
Leprosy (IDEAL) was formed and one of its goals was 
to foster the development of laboratory tests for the di-
agnosis of leprosy (Dockrell et al. 2011). As part of this 
initiative, the present study compared two rapid tests to 
detect anti-PGL-I antibodies against M. leprae in field 
situations in two leprosy endemic countries: Brazil and 
Nepal. In this study, we have used the ML Flow test, 
which detects anti-PGL-I IgM antibodies in whole blood 
and in serum, and the ML- immunochromatography as-
say (ICA) test, which detects anti-PGL-I IgM, IgG and 
IgA antibodies in serum. The results of both lateral flow 
tests were compared in Nepal and Brazil and the agree-
ment between them was reported. The potential appli-
cations, strengths and limitations of these classification 
systems are discussed.
SUBJECTS, MATERIALS AND METHODS
 In this study, the percentage of positive and negative 
ML Flow and ML ICA tests and the agreement between 
these tests were compared among four study groups in 
Brazil and Nepal. Based on the results of these tests, we 
“seroclassified” LPs as MB leprosy (positive serology) 
or PB leprosy (negative serology). This seroclassifica-
tion was compared to other currently used classification 
systems: the WHO operational classification (based on 
the number of lesions), the bacilloscopic index and the 
Ridley and Jopling (1966) classification. 
Study groups - The study populations in Brazil and 
Nepal included four different groups: (i) MB LPs (MB), 
(ii) PB LPs (PB), (iii) healthy household contacts (HHCs) 
of MB LPs and (iv) healthy controls from corresponding 
leprosy endemic control (EC) areas. 
Only newly diagnosed and previously untreated pa-
tients were eligible for inclusion in the Brazilian lepro-
sy groups. In Nepal, patients were also included in the 
study within the first three months after starting MDT. 
Prior to recruitment, all patients were examined by an 
experienced leprosy clinician. LPs were fully character-
ised according to the Ridley and Jopling (1966) criteria 
by taking into account clinical, bacilloscopic and histo-
pathological findings. The disability grade of LPs was 
also assessed (WHO 1988). When serology data were 
used as a tool to aid PB and MB classification in field 
situations, the WHO operational leprosy classification 
system for PB and MB leprosy was employed (WHO 
1998); accordingly, LPs were classified as PB or MB 
based on the number of skin lesions. The presence of 
thickened nerves was not considered. 
HHC were adults without signs or symptoms of lep-
rosy or tuberculosis (TB) and that had lived in the same 
household with an untreated MB patient for at least six 
months. Endemic controls were healthy individuals who 
had no history of TB or leprosy in the family. 
Brazilian LPs were recruited at the main outpatient 
clinic in central-western Brazil (Reference Center for Di-
agnostics and Therapeutics, Goiânia, state of Goiás) from 
February 2007-November 2007. EC were recruited among 
public college students from the same endemic setting. In 
Nepal, participants were recruited from the Anandaban 
Hospital and from Anandaban’s weekly satellite clinic at 
Patan Hospital in Kathmandu between December 2006-
March 2008. EC were recruited from among Nepalese 
college and clinical students visiting for training at the 
Anandaban Hospital or at the satellite clinic.
Test descriptions - Two different lateral flow tests, 
the ML Flow test and the ML ICA test, were used in this 
comparative study. The ML Flow test was manufactured 
by OmegaTeknika Limited (Dublin, Ireland) and by the 
Royal Tropical Institute (KIT, Amsterdam, Netherlands) 
according to the specifications defined by Bührer-
Sékula et al. (2003). The antigen used in the ML Flow 
test to detect IgM antibodies was natural trisaccharide-
phenylpropionyl-bovine serum albumin (NT-P-BSA), a 
semi-synthetic trisaccharide of the PGL-I antigen linked 
to BSA. The ML Flow test employs the same device and 
general protocol for both whole blood and serum sam-
ples. In brief, 5 μL of serum or blood was deposited in 
the sample application receptacle and 130 μL of running 
buffer was added. 
The ML ICA test was developed and produced in 
collaboration with Yonsei University and Standard Di-
agnostics Inc (Suweon, Republic of Korea). The anti-
gens used in the ML ICA test are a semi-synthetic di-
saccharide of the PGL-I antigen bound to human serum 
albumin (ND-O-HSA) or ND-O-BSA. The ML ICA test 
detects IgM, IgG and IgA antibodies. The ML ICA test 
features two different formats: one for whole blood and 
one for serum samples. ML ICA tests were performed 
according to the manufacturer’s recommendations. In 
brief, 15 μL of serum or blood was diluted in 135 μL of 
running buffer and 100 μL of this dilution was deposited 
in the corresponding sample application receptacle. ML 
ICA tests for whole blood did not perform as specified 
by the manufacturer.
The visual readings for both tests were performed 
5-10 min after buffer application. The results were 
scored according to positivity: 0 and 0.5 = negative, 1 +, 
2 +, 3 + and 4 + = positive.
Statistical analyses - Descriptive analyses of clinical 
and epidemiological variables and their frequencies were 
performed. The agreement between the results of indi-
vidual tests was calculated by cross-tabulation and results 
were expressed as percentages with the graduated kappa 
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index (κ): low (0-0.5), moderate (0.51-0.75) and excellent 
(0.76-1), following the Svanholm protocol. The correla-
tion between the results was measured by the correlation 
index (r), in which r = 0 indicates no correlation and r = 1 
indicates perfect positive correlation. Data analysis was 
performed with IBM SPSS statistics version 17.
Ethical issues - In Brazil, this study was approved 
by a local ethics committee (Ethics in Human Research 
and Animal, Hospital of the Federal University of Goiás) 
and by a national ethics committee (National Committee 
for Research Ethics/Brazil). The Nepal Health Research 
Council, under the Ministry of Health of the Govern-
ment of Nepal, also provided ethical approval for this 
study. All study participants provided written, informed 
consent. This study was conducted under the supervi-
sion of the IDEAL Consortium. 
RESULTS
Main characteristics of study participants in Brazil 
and Nepal - The main characteristics of the four study 
groups in Brazil and Nepal are summarised in Table I. 
The total number of participants tested was 363, of which 
180 (49.6%) were tested in Brazil and 183 (50.4%) in Ne-
pal. In both countries, most MB patients were male (62% 
and 80% in Brazil and Nepal, respectively) and 84% of 
EC in Brazil were female. MB and PB LPs in Brazil were 
older than the corresponding patients in Nepal. Among 
the four groups tested in Brazil, the median age was 29 
years and 40% of participants were male; in Nepal, the 
median age was 33 years and 67% of the participants 
were male. Among LPs, a visible BCG scar was present in 
more than 50% of the Brazilian PB group. At both study 
sites, the percentage of visible BCG scars was higher in 
the EC group than in the HHC group. The same percent-
age of BI-positive MB LPs (78%) was detected in Bra-
zil and Nepal. The level of grade 1 disability in the MB 
patient group was comparable in patients in Nepal and 
Brazil, but higher in PB LPs in Nepal than in Brazil. The 
level of grade 2 disability was higher in Nepal in PB and 
MB LPs. In Brazil, the Ridley-Jopling classification was 
available for all patients enrolled. For Nepalese patients, 
Ridley-Jopling classification data were unavailable for 25 
MB patients (46.3%) and 22 PB patients (68.7%). 
ML Flow test results with serum and blood - In Bra-
zil, the ML Flow tests performed with whole blood were 
positive for 84% of MB patients and 31% of PB LPs. All 
HHC and EC patients tested negative with the ML Flow 
test with whole blood. In Nepal, the ML Flow test with 
whole blood was positive for 61% of MB LPs and 3% of 
PB LPs. In the control groups, 8% of HHC and 2% of EC 
were positive.
In Brazil, when serum samples were tested with the 
ML Flow test, 94% of MB patients, 44% of PB patients, 
31% of the HHC group and 2% of the EC group were 
positive. When Nepalese serum samples were tested, 
69% of MB patients, 9% of PB patients, 8% of the HHC 
group and 2% of the EC group were positive according 
to the ML Flow test. 
In Brazil, the agreement of the ML Flow test results 
for blood and serum was greater than 87% (κ = 0.72) 
for all groups with the exception of the HHC, for which 
68.6% agreement (κ = 0.32) was observed. In Nepal, the 
TABLE I
Main characteristics of the multibacillary (MB) and paucibacillary (PB) leprosy patients recruited in Brazil and Nepal
 
 
MB PB HHC EC
Brazil 
(n = 50)
Nepal 
(n = 54)
Brazil 
(n = 45)
Nepal 
(n = 29)
Brazil 
(n = 35)
Nepal 
(n = 49)
Brazil 
(n = 50)
Nepal 
(n = 51)
Sex female [n (%)] 19 (38) 11 (20) 26 (58) 10 (35) 21 (60) 18 (37) 42 (84) 22 (43)
Age (years, range)a 48 (23-100) 35 (16-73) 41 (18-76) 33 (16-64) 29 (18-76) 31 (2-60) 20 (18-56) 21 (17-58)
BCG scar [n (%)] 16 (32) 14 (29) 24 (53) 11 (38) 19 (54) 26 (53) 46 (92) 42(88)
BI positivity [n (%)] 39 (78) 42 (78) 2 (4) 0 NA NA NA NA
Disability grade [n (%)]
   1 15 (30) 16 (30) 2 (4) 6 (19) NA NA NA NA
   2 4 (8) 14 (26) - 3 (6) - - - -
Ridley-Joplingb [n (%)]
   TT 0 1 (2) 19 (42) 1(3) NA NA NA NA
   BT 0 9 (17) 26 (58) 13 (45) - - - -
   BB 9 (18) 0 0 0 - - - -
   BL 13 (26) 11 (20) 0 0 - - - -
   LL 28 (56) 9 (17) 0 0 - - - -
a: median (minimum-maximum); b: in Nepal, 25 MB patients (46.3%) and 22 PB patients (68.7%) did not have data for Ridley 
and Jopling (1966) classification; BB: borderline-boderline; BI: bacilloscopic index; BL: borderline lepromatous; BT: borderline 
tuberculoid; EC: endemic control; HHC: household contact; LL: lepromatous; NA: not applicable; TT: tuberculoid.
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agreement between the results of the ML Flow tests per-
formed with blood and serum was greater than 90% for 
all groups (Table II).
ML ICA test results - In Brazil, there was no differ-
ence between the readings after 5 min or 10 min for ML 
ICA tests performed with serum. In Nepal, the results 
of the ML ICA tests differed at 10 min (data not shown), 
with a 5% increase in positivity vs. readings performed 
at 5 min without effects on specificity. Because the ML 
ICA test for whole blood did not perform as specified 
by the manufacturer, these results were not considered 
in the analysis. 
Agreement between the results of ML ICA and ML 
Flow tests on the serum of LPs - The general agreement 
between the results of the ML ICA and ML Flow tests on 
serum samples in Brazil was 86.3% (κ = 0.71). In a strati-
fied analysis, the agreement between the results for the 
MB patient groups was 96% (κ = 0.73). The agreement 
between the ML ICA and ML Flow tests on serum sam-
ples in Nepal was 72.6% (κ = 0.46). The agreement for 
the MB patient group was 83.3% (κ = 0.55) (Table III). 
The usefulness of the lateral flow tests for leprosy 
classification - The results of the rapid tests were evalu-
ated for their usefulness for PB and MB leprosy classifi-
cation. Most MB LPs are anti-PGL-I positive, whereas 
the majority of PB patients are seronegative. Based on 
this relationship, the ML Flow test seropositivity would 
reclassify as MB 54% (30/56) and 12% (5/41) of the pa-
tients who were previously classified as PB based on le-
sion counting in Brazil and Nepal, respectively (Table 
IV). ML Flow test seronegativity would reclassify as PB 
3% (1/39) and 17% (7/42) of the patients who were classi-
fied as MB based on lesion counting in Brazil and Nepal, 
respectively (Table IV). ML ICA test seropositivity would 
reclassify as MB 34% (19/56) and 46% (19/41) of the PB 
patients in Brazil and Nepal, respectively; ML ICA test 
seronegativity would reclassify as PB 10% (4/39) and 8% 
(5/42) of the patients classified as MB based on lesion 
counting in Brazil and Nepal, respectively (Table V).
ML Flow and ML ICA test seropositivity according 
to the Ridley-Jopling classification and the BI classifi-
cation - The positive rates of the ML Flow and ML ICA 
TABLE II
Agreement between ML Flow tests performed with serum and whole blood
Brazil Nepal
Se+/WB-
(%) Se-/WB+
AGR
(%) k
Se+/WB-
(%) Se-/WB+
AGR
(%) k
MB 10 0 90 0.50 7.4 0 92.6 0.83
PB 12.5 0 87.5 0.73 - 0 93.8 0.47
HHC 31.4 0 68.6 0.32 4.1 4.1 91.8 0.45
EC 2 0 98 0.85 0 0 100 1
Total 12.6 0 87.4 0.72 4.3 1.1 94.6 0.54
AGR: agreement; EC: endemic control; HHC: household contact; k: kappa value; MB: multibacillary; PB: paucibacillary; Se: 
serum; WB: whole blood; +: positive; -: negative. 
TABLE III
Agreement between ML ICA and ML Flow tests with serum in Nepal and Brazil
Brazil Nepal
Flow+/ICA-
(%)
Flow-/ICA+
(%)
AGR
(%) k
Flow+/ICA-
(%)
Flow-/ICA+
(%)
AGR
(%) k
MB 4 0 96 0.73 0 14.8 83.3 0.55
PB 27.1 2.1 70.8 0.36 0 28.1 68.8 0.26
HHC 17.1 5.7 77.1 0.41 0 26.5 59.2 0.17
EC 2 0 98 0.86 0 23.5 76.5 0.11
Total 12 1.6 86.3 0.71 0 22.6 72.6 0.46
readings of ML Flow tests were performed at 10 min. AGR: agreement; EC: endemic control; HHC: household contact; k: kappa 
value; MB: multibacillary; PB: paucibacillary; +: positive; -: negative.
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tests were higher in LL patients than in TT patients (Ta-
ble VI). Table VII shows that the seropositivity rate of 
the ML Flow and ML ICA tests increased with increas-
ing patient BI values in Brazil and Nepal. 
DISCUSSION
Serological studies of leprosy suggest that the detec-
tion of anti-PGL-I antibodies, although specific, should 
not be used for diagnosis, but may be useful for the clas-
sification of MB and PB forms of leprosy (Bührer-Séku-
la et al. 2003, Oskam et al. 2003). Anti-PGL-I testing 
is usually based on the detection of IgM antibodies, but 
the detection of anti-PGL-I IgG and IgA antibodies has 
also been described (Cho et al. 1984, Saad et al. 1991). 
The first rapid anti-PGL-I test (ML Flow test) was de-
veloped based on the detection of IgM antibodies, but 
has low sensitivity in PB leprosy (Bührer-Sékula et al. 
2003). In an attempt to improve the sensitivity of the 
rapid anti-PGL-I test, another format, called ML ICA, 
was developed that simultaneously detects IgM, IgG and 
IgA antibodies. This study compared the results of the 
ML Flow and ML ICA tests and evaluated the applica-
bility of using serological data as an additional tool for 
the classification of PB and MB leprosy.
In an intra-test comparison, there were no statistically 
significant differences among any of the groups when the 
ML Flow test was used with whole blood or serum, in-
dicating that both whole blood and serum can be used. 
These results are consistent with previous studies that 
showed a very strong correlation between the results from 
whole blood and serum (Bührer-Sékula et al. 2003). 
Because the ML ICA test for whole blood did not 
perform according to the manufacturer’s specifications, 
we were only able to use the serum results. With the ML 
ICA tests performed in Nepal, we observed different re-
sults when the tests were read at 5 min and 10 min. Ap-
proximately an additional 5% of the tests became positive 
at the 10 min reading, with no effects on test specificity. 
However, the correlation between the readings at 5 min 
and 10 min was high. When taking all groups into ac-
count, the agreement was very good (94%; k = 0.88). 
Among MB LPs, the correlation between the two read-
ings was even higher, with 98.1% agreement (k = 0.95). 
Due to the higher positive rate among MB patients at the 
10 min reading, we recommend using this time for ML 
ICA tests. When we compared the ML ICA test results 
at 10 min, the correlation among all groups in Brazil and 
Nepal was 97% (k = 0.94). Again, the highest correlation 
was observed in the MB patient groups (99%, k = 0.96).
The inter-test comparison between the ML ICA and 
ML Flow tests with serum samples showed good agree-
ment in Brazil (86.3%; k = 0.71), but the agreement was 
classified as moderate in Nepal (72.6%; k = 0.46). In a 
stratified analysis by study group, only the results for 
MB patients from Brazil and Nepal and for EC from 
Brazil exhibited either very good or good agreement. 
The fair agreement observed with test results for PB pa-
tients and HHC from Brazil and Nepal suggest that (i) 
the higher positive rate in the ML Flow test in Brazil for 
most groups is likely the result of non-specific binding 
in the ML Flow test and (ii) the higher positive response 
of the ML ICA test for all groups in Nepal is most likely 
due to the detection of IgG and IgA antibodies. The high 
agreement between the two tests for the EC group in 
Brazil may be the result of chance equilibrium between 
non-specific binding in the ML Flow test and the detec-
tion of IgG and IgA antibodies by the ML ICA test. This 
possibility is supported by the fact that, in Nepal, none 
of samples that were positive in the ML Flow test were 
negative by the ML ICA test and 22.6% of ML Flow test 
negative samples for all study populations were positive 
in the ML ICA test (Table III). 
TABLE IV
Comparison between classifications based on the number  
of skin lesions and results of ML Flow and smear examination for Brazil and Nepal
Classification based on
WHO lesion counting
Confirmatory tests
Brazil
n (%)
Nepal
n (%)ML Flow Smear
PB patients + + 10 (18) 2 (5) Misclassifieda- + 3 (5) 6 (15)
+ - 20 (36) 3 (7) Confirmed PB- - 23 (41) 30 (73)
Total 56 (59) 41 (49)
MB patients + + 28 (72) 31 (74) Confirmed MBa- + 0 (0) 3 (7)
+ - 10 (26) 4 (10) Misclassified?- - 1 (2) 4 (9)
Total 39 (41) 42 (51)
a: based on smear positivity; MB: multibacillary; PB: paucibacillary; +: positive; -: negative.
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The high agreement between the tests for the MB 
group and the low agreement among other groups could 
be clarified by an analysis of the patients’ operational 
classification based on number of skin lesions. The BI 
positivity for MB patients based on the number of lesions 
was 72% and 81% in Brazil and in Nepal, respectively, 
which led to high positivity for both serological tests. 
The ML Flow test confirmed the MB classification by 
lesion number for 72% and 74% of patients in Brazil and 
in Nepal, respectively and the ML ICA test confirmed 
the MB classification for 67% of patients in Brazil and 
76% of patients in Nepal. 
 Differences were observed among PB LPs classified 
based on the number of lesions. In Brazil, PB patients 
with five or fewer skin lesions had a higher BI positiv-
ity rate (24%) than patients in Nepal (19%). Based on 
this difference, we expected a lower positive rate of se-
rological tests in Nepal and indeed, we observed an ML 
Flow test positivity rate of 12% for PB patients in Nepal, 
compared with 54% in Brazil (p = 0.00002). By contrast, 
47% of PB patients in Nepal were positive according to 
the ML ICA test, compared to 34% of PB patients in 
Brazil. In addition, among the BI-negative PB LPs from 
Nepal, the ML ICA test had a significantly higher posi-
tive rate, 30%, compared to 7% when using the ML Flow 
test (p = 0.0005). The negative results of the ML Flow 
test confirmed the classification of 41% of PB patients in 
Brazil and 73% in Nepal; the ML ICA test confirmed the 
PB classification of 62% and 51% of PB patients in Bra-
zil and Nepal, respectively. The higher positive rate of 
the PB group in Brazil and the lower positive rate of PB 
patients in Nepal of the ML Flow test may be partially 
explained by the diversity in the ratios of leprosy type 
among these populations, particularly when considering 
BT-MB cases. As shown in Table I, whereas some BT 
patients in Nepal were classified as MB, there were no 
such cases in Brazil. Patients in Nepal also had higher 
disability scores than those in Brazil, which may indi-
cate different severities of M. leprae infection among 
these groups. In addition, it is also important to consider 
that these are relatively small samples of large popula-
tions from two different endemic populations. 
Nevertheless, one must also consider the possible ef-
fects of the different carrier proteins used for the PGL-I 
carbohydrate portion of the neoglycoprotein antigens. 
The ML ICA test uses both BSA and HSA, while the 
ML Flow test uses only BSA, a protein to which humans 
can produce antibodies, which may lead to non-specific 
binding and interfere with the test results. The higher 
positive rate of the ML ICA test among PB patients in 
Brazil and Nepal compared to the ML Flow test may be 
due to the detection of specific IgA and IgG antibod-
ies to PGL-I, as has been observed in previous studies 
(Chujor et al. 1991).
 Overall, our results indicate that the addition of an-
ti-IgG and anti-IgA antibody detection in the ML ICA 
test did not improve the sensitivity of the test sufficient-
ly to warrant its use as a diagnostic test. Moreover, if 
the goal of the test is to aid in the classification of PB 
and MB leprosy, it may be advantageous to detect only 
anti-PGL-I IgM antibodies as these results more clearly 
differentiate between PB and MB leprosy. This distinc-
tion is important for treatment purposes. As observed 
in Nepal, when considering the number of lesions, the 
performance of the ML Flow test was superior: seroposi-
tivity confirmed the correct classification of 74% of MB 
patients and seronegativity confirmed the operational 
classification of 73% of PB patients. These results in-
dicate that the anti-PGL-I ML Flow test can be a useful 
tool for the correct classification of MB and PB LPs in 
TABLE V
Comparison between classifications based on the number of skin lesions and results of ML ICA and smear examination for 
Brazil and Nepal
Classification based on
WHO lesion counting
Confirmatory tests
Brazil
n (%)
Nepal
n (%)ML ICA Smear
PB patients + + 11 (20) 7 (17) Misclassifieda- + 2 (4) 1 (2)
+ - 8 (14) 12 (30) Confirmed PB- - 35 (62) 21 (51)
Total PB 56 (59) 41 (49)
MB patients + + 26 (67) 32 (76) Confirmed MBa- + 2 (5) 2 (5)  
+ - 9 (23) 5 (12) Misclassified?- - 2 (5) 3 (7)  
Total MB 39 (41) 42 (51)
a: based on smear positivity; MB: multibacillary; PB: paucibacillary; +: positive; -: negative.
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this population to facilitate better treatment decisions. 
This type of additional testing may help identify those 
clinically diagnosed (by lesion counting or negative BI) 
PB patients that should be reconsidered for MB treat-
ment. Clinicians lacking access to smears could use anti-
PGL-I serology to further test uncertain PB cases before 
assigning treatment.
In the Brazilian subjects, the ML Flow test confirmed 
the correct classification of 41% of PB patients and 72% 
of MB patients. This lower confirmation rate for PB lep-
rosy may indicate that using HSA instead of BSA as the 
neoglycolipid carrier in the ML Flow test could enhance 
the specificity of the test. 
From an operational standpoint, the ML Flow test 
format has advantages over the ML ICA format because 
a single test format can be used for both whole blood 
and serum samples. In addition, the ML Flow test comes 
in individual packages, while the ML ICA test comes 
in packs of 10 cassettes each; once opened, the stabil-
ity of unused tests may be impaired. Moreover, from a 
practical perspective, the ML ICA test is slightly more 
difficult to implement because it requires prior sample 
serum dilution. Nevertheless, the format of any test can 
be optimised to fulfil the needs of the end users, who 
often work in peripheral health clinics with limited fa-
cilities. Because previous serum dilution is not neces-
sary for the ML Flow test, it is the easiest test to perform 
in non-specialised settings. Considering the need for a 
rapid test for use in field situations in endemic countries, 
the use of whole blood samples offers obvious advantag-
es because it is easier to obtain, such as by finger prick 
at the time of consultation, requires less handling and 
can be performed at the POC facility (Bührer-Sékula et 
al. 1998). However, the testing of serum did result in a 
significant gain in sensitivity at both sites and could be 
used for additional or repeat testing if required. 
Although the Ridley-Jopling classification is consid-
ered the gold standard for research purposes, this classi-
fication system is complex and involves clinical, micro-
biological and histopathological criteria. In this study, 
a standardised protocol for Ridley-Jopling classification 
was not used for patients in Nepal and Brazil; therefore, 
we cannot exclude discrepancies due to possible mis-
classifications. Moreover, due to operational constraints, 
the Ridley-Jopling classification was available for only 
approximately half of the Nepalese patients, which lim-
ited the analysis. The WHO operational classification 
for MB and PB leprosy (skin lesion counting) also has 
shortcomings, but it has been considered useful in low-
income leprosy endemic countries. The classification of 
MB and PB leprosy based on anti PGL-I serology also 
has limitations because not all MB patients are seroposi-
tive. In this regard, one of the limitations of the lateral 
flow test is that visual readings may lead to a reading 
bias towards MB positivity and PB negativity if they are 
not blinded from the clinical classification. Therefore, 
we cannot exclude the possibility that operational proce-
dures may have had an impact on the POC test results. 
When considering the Ridley-Jopling classification, 
TABLE VI
Comparison between Ridley-Jopling classification  
and results of ML Flow and ML ICA for Brazil and Nepal
Brazil 
(n = 95)
Nepal 
(n = 44)
Positive
n (%)
Negative
n (%)
Positive
n (%)
Negative
n (%)
Ridley-Joplinga ML Flow
TT 10 (53) 9 (47) 0 (0) 2 (100)
BT 12 (46) 14 (54) 9 (41) 13 (59)
BB 6 (67) 3 (33) 0 (0) -
BL 12 (92) 1 (8) 10 (91) 1 (9)
LL 28 (100) - 8 (100) -
ML ICA
TT 4 (21) 15 (79) 0 (0) 2 (100)
BT 6 (23) 20 (77) 14 (61) 9 (39)
BB 5 (55) 4 (45) 0 (0) -
BL 11(85) 2 (15) 11 (100) -
LL 28 (100) - 8 (100) -
a: Ridley and Jopling (1966) classification; BB: borderline-
boderline; BL: borderline lepromatous; BT: borderline tuber-
culoid; LL: lepromatous; TT: tuberculoid.
TABLE VII 
Comparison between results of bacterial index (BI),  
ML Flow and ML ICA for Brazil and Nepal
Brazil
(n = 95)
Nepal
(n = 83)
Positive
n (%)
Negative
n (%)
Positive
n (%)
Negative
n (%)
BI ML Flow
0 30 (56) 24 (44) 7 (17) 34 (83)
1 8 (80) 2 (20) 6 (55) 5 (45)
2 8 (89) 1 (11) 3 (60) 2 (40)
3 9 (100) - 6 (86) 1 (14)
4 9 (100) - 15 (94) 1 (6)
5 3 (100) - 3 (100) -
6 1 (100) - - -
ML ICA
0 17 (31) 37 (69) 17 (41) 24 (59)
1 9 (90) 1 (10) 10 (91) 1 (9)
2 8 (89) 1 (11) 4 (80) 1 (20)
3 8 (89) 1 (11) 7 (100) -
4 9 (100) - 15 (94) 1 (6)
5 2 (67) 1 (33) 3 (100) -
6 1 (100) - - -
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the positive rate of the ML Flow test was higher in LL 
patients than in TT patients (56% vs. 0%) (Table VI), 
which most likely reflects the increase in the bacillary 
load of the patients in Brazil. Only newly diagnosed, 
untreated Brazilian patients were enrolled. The Ridley-
Jopling classification could not have interfered with the 
readings because the histopathology and BI results were 
not available at the POC facility when the patients were 
diagnosed and tested. Despite the limitations of serology 
for diagnosing or classifying leprosy, the identification 
of MB patients by serology will remain important: MB 
patients are the main source of transmission and after 
MDT they present a higher risk for relapse and leprosy-
related reactions, which are the main cause of deformi-
ties and incapacities. Therefore, any tool that may aid the 
identification of MB LPs with a higher risk for compli-
cations may contribute to improved patient management 
and leprosy control in endemic countries.
Our results demonstrate that when the different anti-
PGL-I POC tests were performed to facilitate the opera-
tional classification of PB and MB leprosy for treatment 
purposes, the ML Flow test was the best POC test for pa-
tients from Nepal. Despite the need for sample dilution, 
the ML ICA test gave better results than the ML Flow 
test in the Brazilian group. Our results identified possible 
ways to improve the performance of both tests. As a POC 
test to classify patients as PB or MB for treatment pur-
poses, anti PGL-I serology should involve the use of un-
diluted whole blood samples to detect IgM antibodies to 
the neoglycolipid conjugated to the HSA antigen carrier. 
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